Trade Vanda - VNDA CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 4.73 |
| Open | 4.81 |
| 1-Year Change | -21.41% |
| Day's Range | 4.61 - 4.86 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 30, 2024 | 4.73 | 0.00 | 0.00% | 4.73 | 4.79 | 4.68 |
| Apr 29, 2024 | 4.80 | 0.15 | 3.23% | 4.65 | 4.82 | 4.65 |
| Apr 26, 2024 | 4.59 | 0.14 | 3.15% | 4.45 | 4.60 | 4.42 |
| Apr 25, 2024 | 4.46 | -0.06 | -1.33% | 4.52 | 4.54 | 4.41 |
| Apr 24, 2024 | 4.54 | -0.06 | -1.30% | 4.60 | 4.65 | 4.53 |
| Apr 23, 2024 | 4.61 | -0.14 | -2.95% | 4.75 | 4.84 | 4.60 |
| Apr 22, 2024 | 4.78 | -0.28 | -5.53% | 5.06 | 5.06 | 4.76 |
| Apr 19, 2024 | 5.09 | 0.18 | 3.67% | 4.91 | 5.27 | 4.90 |
| Apr 18, 2024 | 4.95 | -0.16 | -3.13% | 5.11 | 5.22 | 4.87 |
| Apr 17, 2024 | 5.21 | -0.04 | -0.76% | 5.25 | 5.64 | 4.97 |
| Apr 16, 2024 | 4.02 | 0.04 | 1.01% | 3.98 | 4.05 | 3.96 |
| Apr 15, 2024 | 4.03 | -0.06 | -1.47% | 4.09 | 4.14 | 3.99 |
| Apr 12, 2024 | 4.10 | -0.11 | -2.61% | 4.21 | 4.27 | 4.06 |
| Apr 11, 2024 | 4.26 | 0.03 | 0.71% | 4.23 | 4.29 | 4.16 |
| Apr 10, 2024 | 4.25 | 0.07 | 1.67% | 4.18 | 4.33 | 4.11 |
| Apr 9, 2024 | 4.34 | -0.05 | -1.14% | 4.39 | 4.65 | 4.32 |
| Apr 8, 2024 | 4.49 | -0.29 | -6.07% | 4.78 | 4.80 | 4.47 |
| Apr 5, 2024 | 4.80 | -0.10 | -2.04% | 4.90 | 4.96 | 4.77 |
| Apr 4, 2024 | 4.89 | -0.16 | -3.17% | 5.05 | 5.41 | 4.82 |
| Apr 3, 2024 | 5.02 | 0.44 | 9.61% | 4.58 | 6.00 | 4.35 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Vanda Company profile
About Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its commercial portfolio consists of two products, HETLIOZ (tasimelteon) for the treatment of jet lag disorder, pediatric non-24, delayed sleep phase disorder (DSPD) and autism spectrum disorder (ASD), and Fanapt (iloperidone) for the treatment of bipolar disorder and Parkinson's disease psychosis (PDP) and a long acting injectable (LAI) formulation for the treatment of schizophrenia. Its other product pipeline includes Tradipitant (VLY-686), VTR-297, VSJ-110 and BPO-27. VLY-686, is for the treatment of gastroparesis, motion sickness, atopic dermatitis and COVID-19 pneumonia. VTR-297, is for the treatment of hematologic malignancies. VSJ-110, is for the treatment of dry eye and ocular inflammation. BPO-27, is for the treatment of secretory diarrhea disorders, including cholera. Its other product includes VQW-765.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Vanda Pharmaceuticals Inc. revenues increased 8% to $268.7M. Net income increased 42% to $33.2M. Revenues reflect Hetlioz segment increase of 8% to $173.5M, Fanapt segment increase of 9% to $95.1M. Net income benefited from Selling, General and administrative - decrease of 10% to $105.9M (expense), Advertising Expenses decrease of 47% to $6.7M (expense).
Equity composition
Common Stock $.001 Par, 04/11, 150M auth., 28,103,441 issd. Insiders own 1.56%. 4/18/06 IPO: 5.8M shs. @ $10 per shareby JP Morgan Securities, Inc.
| Industry: | Bio Therapeutic Drugs |
Suite 300E
2200 Pennsylvania Ave Nw
WASHINGTON
WASHINGTON DC 20037
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com